TISIDB

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Single-pass type I membrane protein.
Domain	PF00008 EGF-like domain PF00059 Lectin C-type domain PF00084 Sushi repeat (SCR repeat)
Function	Cell-surface glycoprotein having a role in immunoadhesion. Mediates in the adhesion of blood neutrophils in cytokine-activated endothelium through interaction with SELPLG/PSGL1. May have a role in capillary morphogenesis.

> Gene Ontology [ TOP ]
Biological Process	GO:0002090 regulation of receptor internalization GO:0002092 positive regulation of receptor internalization GO:0002237 response to molecule of bacterial origin GO:0002523 leukocyte migration involved in inflammatory response GO:0006898 receptor-mediated endocytosis GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007159 leukocyte cell-cell adhesion GO:0007202 activation of phospholipase C activity GO:0010517 regulation of phospholipase activity GO:0010518 positive regulation of phospholipase activity GO:0010863 positive regulation of phospholipase C activity GO:0019722 calcium-mediated signaling GO:0019932 second-messenger-mediated signaling GO:0030100 regulation of endocytosis GO:0031623 receptor internalization GO:0032496 response to lipopolysaccharide GO:0034612 response to tumor necrosis factor GO:0043112 receptor metabolic process GO:0045123 cellular extravasation GO:0045807 positive regulation of endocytosis GO:0048259 regulation of receptor-mediated endocytosis GO:0048260 positive regulation of receptor-mediated endocytosis GO:0050727 regulation of inflammatory response GO:0050900 leukocyte migration GO:0050901 leukocyte tethering or rolling GO:0060191 regulation of lipase activity GO:0060193 positive regulation of lipase activity GO:0060627 regulation of vesicle-mediated transport GO:0061756 leukocyte adhesion to vascular endothelial cell GO:0070555 response to interleukin-1 GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules GO:1900274 regulation of phospholipase C activity
Molecular Function	GO:0030246 carbohydrate binding GO:0031406 carboxylic acid binding GO:0033691 sialic acid binding GO:0043168 anion binding GO:0043274 phospholipase binding GO:0070492 oligosaccharide binding
Cellular Component	GO:0005901 caveola GO:0005905 clathrin-coated pit GO:0005938 cell cortex GO:0030863 cortical cytoskeleton GO:0044448 cell cortex part GO:0044853 plasma membrane raft GO:0045121 membrane raft GO:0098589 membrane region GO:0098857 membrane microdomain GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04514 Cell adhesion molecules (CAMs) hsa04668 TNF signaling pathway
Reactome	R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-109582: Hemostasis

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SELE and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SELE and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
18794336	Squamous Cell Carcinoma	Promote immunity	Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. We found that blood vessels in SCCs did not express E-selectin, and tumors contained few cutaneous lymphocyte antigen (CLA)(+) T cells, the cell type thought to provide cutaneous immunosurveillance.
17473183	Metastatic Melanoma	Promote immunity (infiltration)	Results show that the majority of metastatic melanoma samples examined do not express the vascular adhesion receptors E-selectin (CD62E), P-selectin (CD62P), and intercellular adhesion molecule-1 (CD54) on vessels within the tumor boundaries. This results in a block to recruitment of activated tumor-specific CTL to melanoma metastases and is a likely factor limiting the effectiveness of current immunotherapy protocols.
21926464	Melanoma	Promote immunity (infiltration)	Inflammatory cytokines such as IL-6 exert tumor-promoting activities by driving growth and survival of neoplastic cells. Mechanistically, IL-6 produced by nonhematopoietic stromal cells acted cooperatively with soluble IL-6 receptor-α and thermally induced gp130 to promote E/P-selectin- and ICAM-1-dependent extravasation of cytotoxic T cells in tumors.

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SELE in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SELE in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.249	0.648
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.427	0.656
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.128	0.866
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.223	0.149
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-2.285	0.183
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.117	0.955
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.579	0.435
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.887	0.423
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.278	0.812
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.574	0.575
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	2.391	0.0473
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.273	0.346

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SELE in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	4.1	7	0.339
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	5.1	6	0.373
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	19	0	19	0.113
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	25	0	25	0.473
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	0	15.4	0.482
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	3.7	4.2	0.636
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SELE. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SELE. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SELE. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SELE. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SELE expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SELE and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SELE
Name	selectin E
Aliases	ESEL; CD62E; ELAM1; ELAM; endothelial adhesion molecule 1; LECAM2; CD62 antigen-like family member E; ELAM-1 ......
Chromosomal Location	1q24.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SELE collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SELE.

ID	Name	Drug Type	Targets	#Targets
DB01136	Carvedilol	Small Molecule	ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, GJA1 ......	17
DB03721	N-acetyl-alpha-neuraminic acid	Small Molecule	AZGP1, CES1, MBL2, REG1A, SELE, SELP, SIGLEC1	7

Browse SELE